Chloroquine inhibits stimulated platelets at the arachidonic acid pathway.
Chloroquine inhibited arachidonic acid liberation from membrane phospholipids of thrombin- and A23187- stimulated platelets. In addition, it dose-dependently inhibited stimulated malondialdehyde formation and thromboxane B2 generation in the same platelets. The linear correlation between the inhibition of arachidonic acid liberation and malondialdehyde formation indicated that chloroquine inhibited activated phospholipase A2 in thrombin-stimulated platelets, similarly as it does in different cells and tissues. Yet, the nonlinear relationship between arachidonic acid liberation along with malondialdehyde formation and thromboxane generation as well as aggregation suggest that phospholipase A2 does not seem to be the only site of chloroquine action. Rather, it may affect platelets either at other levels of the arachidonic acid cascade too, or at some different stimulatory pathways, like intraplatelet calcium mobilisation, phosphoinositide cycle, calmodulin and protein kinase C activation.
Nosál
R
R
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava.
Jancinová
V
V
Petríková
M
M
D000818:Animals; D016718:Arachidonic Acid / Q000097:blood*; D000001:Calcimycin / Q000037:antagonists & inhibitors; D002738:Chloroquine / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008563:Membrane Lipids / Q000097:blood*; D010743:Phospholipids / Q000097:blood*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013268:Stimulation, Chemical; D013917:Thrombin / Q000037:antagonists & inhibitors; D013931:Thromboxanes / Q000096:biosynthesis / Q000097:blood
D008563:Membrane Lipids; D010743:Phospholipids; D010975:Platelet Aggregation Inhibitors; D013931:Thromboxanes; D016718:Arachidonic Acid; D000001:Calcimycin; D008315:Malondialdehyde; D002738:Chloroquine; D013917:Thrombin